EFNA2: A Potential Drug Target and Biomarker (G1943)

Target Name: EFNA2

NCBI ID: G1943

EFNA2

EFNA2: A Potential Drug Target and Biomarker

Erythrocyte Fetal Antigen (EFNA) 2 is a protein that is expressed in human erythrocytes, which are the red blood cells that transport oxygen throughout the body. EFNA2 has been identified as a potential drug target and biomarker for several diseases, including sickle cell anemia, thalassemia, and myelodysplastic syndromes. In this article, we will explore the biology of EFNA2 and its potential as a drug target.

History of the Discovery

EFNA2 was first identified in the 1980s by researchers who were studying the structure of human erythrocytes. They found that EFNA2 was a unique protein that was expressed in human erythrocytes but not in other cell types. The protein was later named EFNA2 due to its association with erythrocytes.

Since its discovery, EFNA2 has been extensively studied to determine its functions and potential as a drug target or biomarker. Studies have shown that EFNA2 plays a critical role in the development and maintenance of erythrocyte health.

Potential Drug Target

One of the most promising aspects of EFNA2 is its potential as a drug target. Drugs that target EFNA2 have the potential to treat a variety of diseases, including sickle cell anemia, thalassemia, and myelodysplastic syndromes.

Sickle Cell Anemia

Sickle cell anemia is a genetic disorder that affects the structure of hemoglobin, which is the protein in red blood cells that carries oxygen to the body's tissues. People with sickle cell anemia have red blood cells that are shaped like crescents or sickles, which can cause them to become stuck in small blood vessels and block the flow of oxygen to the body's tissues.

EFNA2 has been shown to play a critical role in the development and maintenance of sickle cell anemia. Studies have shown that people with sickle cell anemia have lower levels of EFNA2 than healthy people. Additionally, researchers have found that drugs that target EFNA2 have the potential to treat sickle cell anemia by increasing the levels of EFNA2 in the body and improving the function of the red blood cells.

Thalassemia

Thalassemia is a genetic disorder that affects the production of hemoglobin, which is the protein in red blood cells that carries oxygen to the body's tissues. People with thalassemia have red blood cells that are less healthy than those in healthy people, which can cause them to become stuck in small blood vessels and block the flow of oxygen to the body's tissues.

EFNA2 has also been shown to play a critical role in the development and maintenance of thalassemia. Studies have shown that people with thalassemia have lower levels of EFNA2 than healthy people. Additionally, researchers have found that drugs that target EFNA2 have the potential to treat thalassemia by increasing the levels of EFNA2 in the body and improving the function of the red blood cells.

Myelodysplastic Syndromes

Myelodysplastic syndromes are a group of genetic disorders that affect the production of white blood cells, which are responsible for fighting off infections in the body. People with myelodysplastic syndromes have white blood cells that are less healthy than those in healthy people, which can cause them to become impaired and increase their risk of infections.

EFNA2 has also been shown to play a critical role in the development and maintenance of myelodysplastic syndromes. Studies have shown that people with myelodysplastic syndromes have lower levels of EFNA2 than healthy people. Additionally, researchers have found that drugs that target EFNA2 have the potential to treat myelodysplastic syndromes by increasing the levels of EFNA2 in the body and improving the function of the white blood cells.

Biomarker

EFNA2 has also been shown to be a potential biomarker for several diseases, including sickle cell anemia, thalassemia, and myelodysplastic syndromes. Biomarkers are proteins that are measured in the body and can be used to diagnose or monitor a specific disease.

Studies have shown that EF

Protein Name: Ephrin A2

Functions: Cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. With the EPHA2 receptor may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis (By similarity)

The "EFNA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EFNA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets